[Systemic evaluation and Meta-analysis of efficacy and safety of Kangfu Xiaoyan Suppository in treatment of pelvic inflammatory disease].

To evaluate the efficacy and safety of Kangfu Xiaoyan Suppository in the treatment of pelvic inflammatory disease. Four Chinese databases,namely CNKI,VIP,WanFang and SinoMed,and three English databases Cochrane Library,namely Medline,and ClinicalTrail.gov were systematically and comprehensively retrieved from the establishment of each database to June 2018. The quality of the included studies was evaluated by using the risk assessment tools developed by the Cochrane Collaboration,and RevMan 5. 3 software was used for Meta-analysis. A total of 675 articles were retrieved,and finally 56 studies were included. The total sample size was 6 228,the test group included 3 267 cases,and the control group included 2 961 cases. The overall quality of the included studies was generally low. According to the intervention measures and outcome indicators,the included studies were divided into different subgroups for analysis. The main results of Meta-analysis showed that the recurrence rate of Kangfu Xiaoyan Suppository combined with antibiotics was lower than that of antibiotics alone. Kangfu Xiaoyan Suppository combined with antibiotics was superior to antibiotics alone in terms of abdominal pain,leucorrhea abnormality relief time,mass absorption time and pain relief time. In terms of safety,Kangfu Xiaoyan Suppository combined with antibiotics had a lower incidence of adverse reactions than antibiotics alone. Based on the results of this study,it is indicated that Kangfu Xiaoyan Suppository had a certain effect on the treatment of pelvic inflammatory disease,especially with a lower recurrence rate. The long-term effect is remarkable. No serious adverse reaction was observed. Restricted by the quality of the studies included,the above conclusion need to be further verified in high-quality,largesize,multi-center clinical researches.

[Expert consensus statement on Kangfu Xiaoyan Suppository in treatment of pelvic inflammatory in clinical practice].

Kangfu Xiaoyan Suppository is widely used in the treatment of gynecological inflammatory diseases. Long-term clinical application and a certain amount of research evidences show that Kangfu Xiaoyan Suppository can alleviate the clinical symptoms of pelvic inflammatory diseases,reduce the recurrence rate,and relieve sequelae,with a better safety and economic characteristics. As a type of nationally protected traditional Chinese medicine and type B medicine included in medical insurance,it has been selected as a Chinese patent medicine for rectal administration. It was included in the Guidelines for diagnosis and treatment of common gynecological diseases of traditional Chinese medicine published by the Chinese Academy of Traditional Chinese Medicine in 2012,the Pelvic inflammatory diseases diagnosis and treatment guidelines issued by the Infectious Diseases Collaborative Group of the Obstetrics and Gynecology Branch of the Chinese Medical Association in 2014,and the group standard of Single use of traditional Chinese medicine/combined antibiot guidelines for clinical practice-pelvic inflammatory diseases of the Chinese Academy of Traditional Chinese Medicine in 2017. To further enhance clinicians' understanding of the drug and better guide its rational clinical use,experts from the field of gynecology of traditional Chinese and Western medicine were invited to develop and compile this expert consensus. This consensus takes full account of clinical evidences and expert clinical experience,and form recommendations for clinical problems based on evidences and consensus recommendations for clinical problems without evidence by nominal grouping method. The expert consensus is mainly formed in the consideration of six factors: quality of evidence,economy,efficacy,adverse reactions,patient acceptability and others. Based on clinical research evidences and expert experience,this consensus provides a preliminary reference for the clinical use of the drug in a concise and clear format. However,evidence-based support is still required in a large number of high-quality studies,and this consensus will be revised in the future according to new clinical problems and the update of evidence-based evidence in practical application.

Expert consensus statement on Kangfu Xiaoyan Suppository in treatment of pelvic inflammatory in clinical practice / 中国中药杂志

Kangfu Xiaoyan Suppository is widely used in the treatment of gynecological inflammatory diseases. Long-term clinical application and a certain amount of research evidences show that Kangfu Xiaoyan Suppository can alleviate the clinical symptoms of pelvic inflammatory diseases,reduce the recurrence rate,and relieve sequelae,with a better safety and economic characteristics. As a type of nationally protected traditional Chinese medicine and type B medicine included in medical insurance,it has been selected as a Chinese patent medicine for rectal administration. It was included in the Guidelines for diagnosis and treatment of common gynecological diseases of traditional Chinese medicine published by the Chinese Academy of Traditional Chinese Medicine in 2012,the Pelvic inflammatory diseases diagnosis and treatment guidelines issued by the Infectious Diseases Collaborative Group of the Obstetrics and Gynecology Branch of the Chinese Medical Association in 2014,and the group standard of Single use of traditional Chinese medicine/combined antibiot guidelines for clinical practice-pelvic inflammatory diseases of the Chinese Academy of Traditional Chinese Medicine in 2017. To further enhance clinicians' understanding of the drug and better guide its rational clinical use,experts from the field of gynecology of traditional Chinese and Western medicine were invited to develop and compile this expert consensus. This consensus takes full account of clinical evidences and expert clinical experience,and form recommendations for clinical problems based on evidences and consensus recommendations for clinical problems without evidence by nominal grouping method. The expert consensus is mainly formed in the consideration of six factors: quality of evidence,economy,efficacy,adverse reactions,patient acceptability and others. Based on clinical research evidences and expert experience,this consensus provides a preliminary reference for the clinical use of the drug in a concise and clear format. However,evidence-based support is still required in a large number of high-quality studies,and this consensus will be revised in the future according to new clinical problems and the update of evidence-based evidence in practical application.

Systemic evaluation and Meta-analysis of efficacy and safety of Kangfu Xiaoyan Suppository in treatment of pelvic inflammatory disease / 中国中药杂志

To evaluate the efficacy and safety of Kangfu Xiaoyan Suppository in the treatment of pelvic inflammatory disease. Four Chinese databases,namely CNKI,VIP,WanFang and SinoMed,and three English databases Cochrane Library,namely Medline,and ClinicalTrail.gov were systematically and comprehensively retrieved from the establishment of each database to June 2018. The quality of the included studies was evaluated by using the risk assessment tools developed by the Cochrane Collaboration,and RevMan 5. 3 software was used for Meta-analysis. A total of 675 articles were retrieved,and finally 56 studies were included. The total sample size was 6 228,the test group included 3 267 cases,and the control group included 2 961 cases. The overall quality of the included studies was generally low. According to the intervention measures and outcome indicators,the included studies were divided into different subgroups for analysis. The main results of Meta-analysis showed that the recurrence rate of Kangfu Xiaoyan Suppository combined with antibiotics was lower than that of antibiotics alone. Kangfu Xiaoyan Suppository combined with antibiotics was superior to antibiotics alone in terms of abdominal pain,leucorrhea abnormality relief time,mass absorption time and pain relief time. In terms of safety,Kangfu Xiaoyan Suppository combined with antibiotics had a lower incidence of adverse reactions than antibiotics alone. Based on the results of this study,it is indicated that Kangfu Xiaoyan Suppository had a certain effect on the treatment of pelvic inflammatory disease,especially with a lower recurrence rate. The long-term effect is remarkable. No serious adverse reaction was observed. Restricted by the quality of the studies included,the above conclusion need to be further verified in high-quality,largesize,multi-center clinical researches.

Analysis of curative effect of Kangfu Xiaoyan suppository in 166 cases of postpartum rehabilitation / 中国实用妇科与产科杂志

OBJECTIVE: To observe the curative effect of Kangfu Xiaoyan suppository on the recovery of uterus andpostpartum pain in postpartum women.METHODS: A total of 166 cases of postpartum women were divided into cesareansection group and normal delivery group,and each group was again divided into treatment group and control group.Thenthe women in treatment group were given the rectum use of Kangfu Xiaoyan suppository in the morning and evening 12 hours after delivery.The effects on uterine recovery,vaginal bleeding and postpartum pain were compared among eachgroup.RESULTS: The amount of vaginal bleeding and the scores of uterine contraction pain and anus drop pain incaesarean section treatment group were significantly lower than those in the control group in three days after surgery(P <0.05).The descending height of the uterine at the first day after delivery was not significantly different from that of thecontrol group;on the second and third day,the descending height was significantly higher than that of the control group(P<0.05).The amount of vaginal bleeding,the scores of uterine contraction pain and anus drop pain in normal deliverytreatment group were significantly lower than those in the control group in three days after surgery(P<0.05).Descendingheight of uterine floor in normal delivery treatment group were significantly higher than those in the control group on thefirst day,the second day and the third day(P<0.05).There was no significant difference in proportion of labium and labiaswelling between the two groups on the first day of postpartum,but on the second and third day was significantly lowerthan that of the control group(P<0.05).CONCLUSION: Kangfu Xiaoyan suppository is an ideal Chinese patent medicinefor postpartum rehabilitation of postpartum woman.

Observation on the effect of Kangfu Xiaoyan suppository combined with ceftriaxone sodium in treating chronic pelvic inflammatory disease / 中国生化药物杂志

Objective To observe the clinical efficacy of treatment of chronic pelvic inflammatory disease with Kangfu Xiaoyan suppository combined ceftriaxone.Methods84 cases of chronic pelvic inflammatory disease in our hospital from June 2015 to August 2016 were randomly divided into observation group and control group, with 42 cases in each group.The control group were treated with ceftriaxone sodium alone,on the basis of the control group, the observation group was treated with Kangfu Xiaoyan suppository.After treatment, the changes tumor necrosis factor-α (TNF-α), transforming growth factor β1 (TGF-β1), interleukin 8,1β (IL-8, IL-1β) and clinical symptom score in the two groups were recorded and analyzed.Results①After two weeks of treatment, the total effective rate of observation group was 92.86%, significantly higher than that of the control group(76.19%), and the difference was statistically significant (P<0.05).②After treatment,the levels of TNF-α, TGF-β1 in the observation group[(0.80±0.23)μg/L, (12.43±1.98)μg/mL) were better than the control group[(1.81±0.35)μg/L,(19.01±2.24)μg/mL], and the differences were statistically significant (P<0.05);③After treatment,the abdominal pain, vaginal symptom score of observation group[(1.57±0.11),(1.45±0.15) points] were lower than the control group[(2.05±0.17),(2.16±0.20) points], and the differences were statistically significant (P<0.05).ConclusionKangfute Xiaoyan Suppository combined with ceftriaxone sodium in the treatment of chronic pelvic inflammatory disease, curative effect is exact, compared with the single application of ceftriaxone sodium in the treatment without obvious adverse reactions, can effectively improve the symptoms of patients with chronic pelvic inflammatory disease, it is worthy of further research and application.